Scarica l'app Stockscreener
2.33
2.92%
-0.07
Dopo l'orario di chiusura:
2.36
0.03
+1.29%
Precedente Chiudi:
$2.40
Aprire:
$2.4
Volume 24 ore:
984.63K
Relative Volume:
0.41
Capitalizzazione di mercato:
$434.87M
Reddito:
$7.12M
Utile/perdita netta:
$-24.17M
Rapporto P/E:
-9.5727
EPS:
-0.2434
Flusso di cassa netto:
$-41.95M
1 W Prestazione:
-4.51%
1M Prestazione:
-6.80%
6M Prestazione:
+37.87%
1 anno Prestazione:
+236.22%
Intervallo 1D:
$2.31
$2.40
Intervallo di 1 settimana:
$2.29
$2.518
Portata 52W:
$0.475
$3.105
Ovid Therapeutics Inc Stock (OVID) Company Profile
Nome
Ovid Therapeutics Inc
Settore
Industria
Telefono
212-776-4381
Indirizzo
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.33 | 434.87M | 7.12M | -24.17M | -41.95M | -0.2434 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Iniziato | Roth Capital | Buy |
| 2025-11-17 | Iniziato | Leerink Partners | Outperform |
| 2025-10-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-08 | Ripresa | B. Riley Securities | Buy |
| 2024-06-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Iniziato | B. Riley Securities | Buy |
| 2024-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-05 | Iniziato | Wedbush | Outperform |
| 2023-12-21 | Iniziato | BTIG Research | Buy |
| 2023-10-13 | Iniziato | Oppenheimer | Outperform |
| 2021-04-20 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-04-20 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
Ovid Therapeutics Inc (OVID) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OVID|Ovid Therapeutics Inc|Price:2.330|Chg%:-0.070 - TradingKey
This Pharmaceutical Stock is a Top Pick at B. Riley - Investing.com UK
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Nigeria
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target - Investing.com
Ovid Therapeutics (OVID) Edges Higher, Holding Above Key Support ZoneMoving Average Ribbon - dars.gov.et
FEDERATED HERMES, INC. Increases Stake in Ovid Therapeutics Inc - GuruFocus
Ovid Therapeutics names new chief business officer By Investing.com - Investing.com Nigeria
Ovid Therapeutics Appoints New Executives to Drive Strategic Growth - sekbernews.id
Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer - Yahoo Finance
Ovid Therapeutics appoints Charles Carter as new CFO - The Globe and Mail
Form 4 Ovid Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
Ovid Therapeutics (ticker: OVID) grants CFO 50,000 RSUs vesting 2027-2028 - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) CFO reports 44,375 shares and long-dated stock options - Stock Titan
Ovid Therapeutics Says Carter Has More Than 30 Yrs of Experience Across Finance, Strategy, Operational Leadership >OVID - Moomoo
PR News | On the Move: Ovid Therapeutics Hires Fort as CSOWed., Jul. 8, 2026 - O'Dwyer's PR
Ovid Therapeutics names new chief business officer - Investing.com
Ovid Therapeutics: Victoria Fort Promoted to Chief Strategy Officer >OVID - Moomoo
Federated Hermes (NASDAQ: OVID) holds 7.74M shares, 4.15% disclosed - Stock Titan
Ovid Therapeutics: Norrett Most Recently Served as Chief Business Officer at Soleno Therapeutics, Where He Led Company's Acquisition by Neurocrine Biosciences >OVID - Moomoo
Ovid Therapeutics: Carter Succeeds Jeffrey Rona, Who Will Remain Long-Term Advisor Through 2027 >OVID - Moomoo
Ovid Therapeutics names Charles Carter as CFO as Jeffrey Rona transitions from finance roles - TradingView
New Ovid Therapeutics (NASDAQ: OVID) CFO named as Rona transitions to consultant - Stock Titan
Ovid Therapeutics Strengthens Executive Leadership Team to - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally - Seeking Alpha
Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329, TSC/IS Expansions - Seeking Alpha
Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth - Sahm
Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2500 Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Value Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Microcap Value Benchmark Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 3000E Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell Microcap Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 3000E Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2500 Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Ovid Therapeutics Inc (OVID) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ovid Therapeutics Inc. Actuals & Estimates (NASDAQ:OVID) - TradingView
OVID Forecast — Price Target — Prediction for 2027 - TradingView
AQST Stock Price and Chart — NASDAQ:AQST - TradingView
1OT Forecast — Price Target — Prediction for 2027 - TradingView
Ovid Therapeutics Inc. Actuals & Estimates (SWB:1OT) - TradingView
Price to book forward of Ovid Therapeutics Inc. – NASDAQ:OVID - TradingView
Price to earnings forward of Ovid Therapeutics Inc. – NASDAQ:OVID - TradingView
Price to sales forward of Ovid Therapeutics Inc. – NASDAQ:OVID - TradingView
Ovid Therapeutics Inc (OVID) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy - Sahm
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to S&P Biotechnology Select Industry Index - marketscreener.com
Ovid Therapeutics Inc Azioni (OVID) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ovid Therapeutics Inc Azioni (OVID) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ALEXANDER MARGARET A. | President and CEO |
Feb 23 '26 |
Sale |
1.45 |
11,656 |
16,901 |
61,750 |
| Rona Jeffrey A | CBFO |
Feb 23 '26 |
Sale |
1.45 |
8,541 |
12,384 |
88,188 |
0.46%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):